Ra Capital Management, L.P. - Feb 28, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: Director
Signature: /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol: CTKB
Transactions as of: Feb 28, 2022
Transactions value $: $5,721,951
Form type: 4
Date filed: 3/2/2022, 04:29 PM
Previous filing: Feb 25, 2022
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Purchase	$113K	+8.75K	+0.08%	$12.97	11.1M	Feb 28, 2022	See footnotes	F1, F2, F3, F8
transaction	CTKB	Common Stock	Purchase	$3.83M	+295K	+2.66%	$12.98	11.4M	Mar 1, 2022	See footnotes	F1, F4, F5, F8
transaction	CTKB	Common Stock	Purchase	$1.78M	+138K	+1.22%	$12.89	11.5M	Mar 2, 2022	See footnotes	F1, F6, F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established December 14, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $12.96 to $13.00; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3	These securities include 9,388,672 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund"), 1,185,767 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and 507,724 shares held by a separately managed account (the "Account").
F4	This transaction was executed in multiple trades at prices ranging from $12.86 to $13.00; the price reported above reflects the weighted average purchase price.
F5	These securities include 9,683,536 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
F6	This transaction was executed in multiple trades at prices ranging from $12.64 to $13.00; the price reported above reflects the weighted average purchase price.
F7	These securities include 9,821,791 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
F8	RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.